Global Head and Neck Cancer Therapeutics Market stood at USD2024.33 million in 2021 and is expected to grow at an impressive rate of 7.22% during the forecast period. Click : https://bit.ly/3sM7H13

1. GLOBAL HEAD AND NECK CANCER THERAPEUTICS
MARKET
2017 – 2027
MARKET INTELLIGENCE . CONSULTING
www.techsciresearch.com
FORECAST & OPPORTUNITIES

2. 2
Scope of Report
Product of Interest (POI): Head and Neck Cancer Therapeutics
Review Period
2017 – 2020
Base Year
2021
Estimated Year
2022
Forecast Period
2023 – 2027
Year Range
DIAGNOSTIC METHODS
REGION
• North America
• Europe
• APAC
• South America
• Middle East & Africa
• Biopsy
• Imaging
• Endoscopy
• Others
Head and neck cancer is a term used to define cancer that develops in the mouth,
throat, nose, salivary glands, oral cancers or other areas of the head and neck. Most
of these cancers are squamous cell carcinomas, or cancers that begin in the lining of
the mouth, nose and throat.
Market Segmentation
DISEASE INDICATION
• Lip and Oral Cavity Cancer
• Laryngeal Cancer
• Oropharyngeal Cancer
• Salivary Gland Cancer
• Nasopharyngeal Cancer
• Hypopharyngeal Cancer
• Surgery
• Radiation Therapy
• Chemotherapy
• Immunotherapy
• Targeted Therapy
TREATMENT TYPE
ROUTE OF ADMINISTRATION
THERAPEUTIC CLASS
END USER
• Injectable
• Oral
• PD Inhibitors
• EGFR Inhibitors
• Microtubule Inhibitors
• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• Others

3. 3
Table of Contents
S. No. Contents Page No.
1.
Product Overview (A brief description of the category and product inclusions considered under the
scope of the study to give clear picture to the client about the product of interest.)
2.
Research Methodology (A detailed methodology on how we have derived the market related
information and what are the measures that has been taken to validate the data.)
3. Executive Summary
4. Voice of Customer
5.
Global Head and Neck Cancer Therapeutics Market Outlook, 2017-2027F (This chapter includes
a brief overview of the product of interest market such as total market’s growth rate, expected
growth rate, key growth levers, leading region, top grossing product types, etc. It includes more of
a qualitative information about the market.)
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Diagnostic Methods (Biopsy, Imaging, Endoscopy, Others)
5.2.2.
By Treatment Type (Surgery, Radiation Therapy, Chemotherapy, Immunotherapy, Targeted
Therapy)
5.2.3.
By Disease Indication (Lip and Oral Cavity Cancer, Laryngeal Cancer,
Oropharyngeal Cancer, Salivary Gland Cancer, Nasopharyngeal Cancer,
Hypopharyngeal Cancer)
5.2.4. By Route of Administration (Injectable, Oral)
5.2.5. By Therapeutic Class (PD Inhibitors, EGFR Inhibitors, Microtubule Inhibitors)
5.2.6. By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)
5.2.7. By Company (2021)
5.2.8. By Region
5.3. Product Market Map

4. 4
Table of Contents
S. No. Contents Page No.
6. Asia-Pacific Head and Neck Cancer Therapeutics Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Diagnostic Methods
6.2.2. By Treatment Type
6.2.3. By Disease Indication
6.2.4. By Route of Administration
6.2.5. By Therapeutic Class
6.2.6. By End-User
6.2.7. By Country
6.3. Asia-Pacific: Country Analysis
6.3.1. China Head and Neck Cancer Therapeutics Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Diagnostic Methods
6.3.1.2.2. By Treatment Type
6.3.1.2.3. By Disease Indication
6.3.1.2.4. By Route of Administration
6.3.1.2.5. By Therapeutic Class
6.3.1.2.6. By End-User

5. 5
Table of Contents
S. No. Contents Page No.
6.3.2. India Head and Neck Cancer Therapeutics Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Diagnostic Methods
6.3.2.2.2. By Treatment Type
6.3.2.2.3. By Disease Indication
6.3.2.2.4. By Route of Administration
6.3.2.2.5. By Therapeutic Class
6.3.2.2.6. By End-User
6.3.3. Japan Head and Neck Cancer Therapeutics Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Diagnostic Methods
6.3.3.2.2. By Treatment Type
6.3.3.2.3. By Disease Indication
6.3.3.2.4. By Route of Administration
6.3.3.2.5. By Therapeutic Class
6.3.3.2.6. By End-User

6. 6
Table of Contents
S. No. Contents Page No.
6.3.4. South Korea Head and Neck Cancer Therapeutics Market Outlook
6.3.4.1. Market Size & Forecast
6.3.4.1.1. By Value
6.3.4.2. Market Share & Forecast
6.3.4.2.1. By Diagnostic Methods
6.3.4.2.2. By Treatment Type
6.3.4.2.3. By Disease Indication
6.3.4.2.4. By Route of Administration
6.3.4.2.5. By Therapeutic Class
6.3.4.2.6. By End-User
6.3.5. Australia Head and Neck Cancer Therapeutics Market Outlook
6.3.5.1. Market Size & Forecast
6.3.5.1.1. By Value
6.3.5.2. Market Share & Forecast
6.3.5.2.1. By Diagnostic Methods
6.3.5.2.2. By Treatment Type
6.3.5.2.3. By Disease Indication
6.3.5.2.4. By Route of Administration
6.3.5.2.5. By Therapeutic Class
6.3.5.2.6. By End-User

7. 7
Table of Contents
S. No. Contents Page No.
6.3.6. Singapore Head and Neck Cancer Therapeutics Market Outlook
6.3.6.1. Market Size & Forecast
6.3.6.1.1. By Value
6.3.6.2. Market Share & Forecast
6.3.6.2.1. By Diagnostic Methods
6.3.5.2.2. By Treatment Type
6.3.6.2.3. By Disease Indication
6.3.6.2.4. By Route of Administration
6.3.6.2.5. By Therapeutic Class
6.3.6.2.6. By End-User
7. Europe Head and Neck Cancer Therapeutics Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Diagnostic Methods
7.2.2. By Treatment Type
7.2.3. By Disease Indication
7.2.4. By Route of Administration
7.2.5. By Therapeutic Class
7.2.6. By End-User
7.2.7. By Country

8. 8
Table of Contents
S. No. Contents Page No.
7.3. Europe: Country Analysis
7.3.1. France Head and Neck Cancer Therapeutics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Diagnostic Methods
7.3.1.2.2. By Treatment Type
7.3.1.2.3. By Disease Indication
7.3.1.2.4. By Route of Administration
7.3.1.2.5. By Therapeutic Class
7.3.1.2.6. By End-User
7.3.2. Germany Head and Neck Cancer Therapeutics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Diagnostic Methods
7.3.2.2.2. By Treatment Type
7.3.2.2.3. By Disease Indication
7.3.2.2.4. By Route of Administration
7.3.2.2.5. By Therapeutic Class
7.3.2.2.6. By End-User

9. 9
Table of Contents
S. No. Contents Page No.
7.3.3. United Kingdom Head and Neck Cancer Therapeutics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Diagnostic Methods
7.3.3.2.2. By Treatment Type
7.3.3.2.3. By Disease Indication
7.3.3.2.4. By Route of Administration
7.3.3.2.5. By Therapeutic Class
7.3.3.2.6. By End-User
7.3.4. Italy Head and Neck Cancer Therapeutics Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Diagnostic Methods
7.3.4.2.2. By Treatment Type
7.3.4.2.3. By Disease Indication
7.3.4.2.4. By Route of Administration
7.3.4.2.5. By Therapeutic Class
7.3.4.2.6. By End-User

10. 10
Table of Contents
S. No. Contents Page No.
7.3.5. Spain Head and Neck Cancer Therapeutics Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Diagnostic Methods
7.3.5.2.2. By Treatment Type
7.3.5.2.3. By Disease Indication
7.3.5.2.4. By Route of Administration
7.3.5.2.5. By Therapeutic Class
7.3.5.2.6. By End-User
8. North America Head and Neck Cancer Therapeutics Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Diagnostic Methods
8.2.2. By Treatment Type
8.2.3. By Disease Indication
8.2.4. By Route of Administration
8.2.5. By Therapeutic Class
8.2.6. By End-User
8.2.7. By Country

11. 11
Table of Contents
S. No. Contents Page No.
8.3. North America: Country Analysis
8.3.1. United States Head and Neck Cancer Therapeutics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Diagnostic Methods
8.3.1.2.2. By Treatment Type
8.3.1.2.3. By Disease Indication
8.3.1.2.4. By Route of Administration
8.3.1.2.5. By Therapeutic Class
8.3.1.2.6. By End-User
8.3.2. Mexico Head and Neck Cancer Therapeutics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Diagnostic Methods
8.3.2.2.2. By Treatment Type
8.3.2.2.3. By Disease Indication
8.3.2.2.4. By Route of Administration
8.3.2.2.5. By Therapeutic Class
8.3.2.2.6. By End-User

12. 12
Table of Contents
S. No. Contents Page No.
8.3.3. Canada Head and Neck Cancer Therapeutics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Diagnostic Methods
8.3.2.2.2. By Treatment Type
8.3.2.2.3. By Disease Indication
8.3.2.2.4. By Route of Administration
8.3.2.2.5. By Therapeutic Class
8.3.2.2.6. By End-User
9. South America Head and Neck Cancer Therapeutics Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Diagnostic Methods
9.2.2. By Treatment Type
9.2.3. By Disease Indication
9.2.4. By Route of Administration
9.2.5. By Therapeutic Class
9.2.6. By End-User
9.2.7. By Country

13. 13
Table of Contents
S. No. Contents Page No.
9.3. South America: Country Analysis
9.3.1. Brazil Head and Neck Cancer Therapeutics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1 By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Diagnostic Methods
9.3.1.2.2. By Treatment Type
9.3.1.2.3. By Disease Indication
9.3.1.2.4. By Route of Administration
9.3.1.2.5. By Therapeutic Class
9.3.1.2.6. By End-User
9.3.2. Argentina Head and Neck Cancer Therapeutics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1 By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Diagnostic Methods
9.3.2.2.2. By Treatment Type
9.3.2.2.3. By Disease Indication
9.3.2.2.4. By Route of Administration
9.3.2.2.5. By Therapeutic Class
9.3.2.2.6. By End-User

14. 14
Table of Contents
S. No. Contents Page No.
9.3.3. Colombia Head and Neck Cancer Therapeutics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1 By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Diagnostic Methods
9.3.2.2.2. By Treatment Type
9.3.2.2.3. By Disease Indication
9.3.2.2.4. By Route of Administration
9.3.2.2.5. By Therapeutic Class
9.3.2.2.6. By End-User
10. Middle East & Africa Head and Neck Cancer Therapeutics Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Diagnostic Methods
10.2.2. By Treatment Type
10.2.3. By Disease Indication
10.2.4. By Route of Administration
10.2.5. By Therapeutic Class
10.2.6. By End-User
10.2.7. By Country

15. 15
Table of Contents
S. No. Contents Page No.
10.3. Middle East & Africa : Country Analysis
10.3.1. South Africa Head and Neck Cancer Therapeutics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Diagnostic Methods
10.3.1.2.2. By Treatment Type
10.3.1.2.3. By Disease Indication
10.3.1.2.4. By Route of Administration
10.3.1.2.5. By Therapeutic Class
10.3.1.2.6. By End-User
10.3.2. Saudi Arabia Head and Neck Cancer Therapeutics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Diagnostic Methods
10.3.2.2.2. By Treatment Type
10.3.2.2.3. By Disease Indication
10.3.2.2.4. By Route of Administration
10.3.2.2.5. By Therapeutic Class
10.3.2.2.6. By End-User

16. 16
Table of Contents
S. No. Contents Page No.
10.3.3. UAE Head and Neck Cancer Therapeutics Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Diagnostic Methods
10.3.3.2.2. By Treatment Type
10.3.3.2.3. By Disease Indication
10.3.3.2.4. By Route of Administration
10.3.3.2.5. By Therapeutic Class
10.3.3.2.6. By End-User
11. Impact of COVID-19 on Global Head and Neck Cancer Therapeutics Market
12. Clinical Trial Analysis
13. Market Dynamics
13.1. Drivers
13.2. Challenges
14.
Market Trends & Developments (This section captures recent trends pertaining to manufacturing or
consumption, market movements in terms of points of production and consumption, advancements and
development)
15. Competitive Landscape

17. 17
Table of Contents
S. No. Contents Page No.
15.1. Competition Outlook
15.2. Company Profiles (Top 10 Companies)
15.2.1. Company Details
15.2.2 Products & Services
15.2.3. Financials (As Reported)
15.2.4. Key Market Focus & Geographical Presence
15.2.5. Recent Developments
15.2.6. Key Management Personnel
16. Strategic Recommendations (Based on the findings of the report strategic recommendations on how
to enter and expand market share)
17. About Us & Disclaimer

18. RESEARCH
METHODOLOGY

19. 19
Research Methodology
✓ Identifying Key Opinion
Leaders
✓ Questionnaire Design
✓ In-depth Interviews
Data
Collection
Developing list
of respondents
Formulating
Questionnaire
Market
Profiling
Data
Validation
Data
Analysis
In-depth secondary
research was conducted to
determine top players in
the global head and neck
cancer therapeutics
market, overall market size
and segmental market size.
In order to conduct
industry experts’
interviews, TechSci
formulated a detailed
discussion guide.
List of industry
players and industry
specialists was
developed.
TechSci conducted
interviews with
industry experts and
industry players for
data collection and
verification.
Data obtained as a
result of primary
and secondary
research was
validated through
rigorous
triangulation.
The data was scrutinized
using MS-Excel, statistical
tools and internal
proprietary database to
obtain qualitative and
quantitative insights about
the global head and neck
cancer therapeutics market
Data
Collection
Data Filter
& Analysis
Research &
Intelligence
Actionable
Insights
Business
Solution
Primary Research Desk Research Company Analysis
✓ Recent Developments
✓ Market Changing
Aspects/Dynamics
✓ Government Policies
✓ Final Conclusion
✓ Market Participants
✓ Key Strengths
✓ LinkedIn
✓ TechSci Internal
Database
✓ Factiva
✓ Hoovers
Paid Sources
✓ Company Website
✓ Company Annual
Reports
✓ White Paper Study
✓ Financial Reports
✓ Investor
Presentations
✓ Regulatory Body
✓ Associations, etc.
Secondary
Research
Primary Research

20. 20
Research Methodology
Baseline Methodology
Our dedicated team of industry experts has monitored and analyzed various aspects of global head and neck cancer therapeutics market. The
team has analyzed the outlook of various segments of this market, while considering the major influencing factors such as rising patient pool
suffering from head and neck cancer around the world and speculated a positive growth during the next 5 years. The study includes market
forecasting, which would enable our clients to take better decisions while planning their strategy to achieve sustainability in global head and
neck cancer therapeutics market.
Methodology Followed for Calculation of Market Size:
• Market Size by Value: Market size, in terms of value, for the year 2021 was calculated based on information collected through exhaustive
secondary research and primary surveys, with various key opinion leaders/stakeholders, such as head and neck cancer therapeutics
companies, channel partners, market influencers & end users, industry experts, and other industry participants.
• The team interviewed more than 15 – 20 head and neck cancer therapeutics companies, 45 – 50 channel partners, 80 – 100 end users, and
15 – 20 Industry experts and other value chain stakeholders in global head and neck cancer therapeutics market to obtain the overall market
size from 2017-2021, which was validated by the Delphi technique. Taking standard deviation into consideration, the market size was
averaged out, to arrive at the market size data from 2017-2021.

21. 21
Research Methodology
• Respondents were asked about the current and future market growth rates, market shares by diagnostic methods, by treatment type, by
disease indication, by route of administration, by therapeutic class, by end user, by company and by region. Removing the outlier responses,
the geometric mean of growth estimates and supplier wise revenue shares generated across various segments were considered, to arrive at
the final revenue shares. Revenue shares generated across various segments were further triangulated from other stakeholders depending
upon the type of head and neck cancer therapeutics.
Methodology Followed for Calculation of Market Shares:
Market shares by diagnostic methods, by treatment type, by disease indication, by route of administration, by therapeutic class, by end user, by
company and by region were calculated based on the responses received through primary surveys with industry experts, in which the
respondents were asked about the market shares or revenue generated from various type of head and neck cancer therapeutics. The final
shares were calculated by taking the geometric mean of the responses gathered from key opinion leaders after eliminating the outliers.
Methodology Followed for Forecasting:
• TechSci Research performed periodical checks on data collected through the surveys with logic checks and analyzed the survey results in
SPSS/Tableau Software.
• Data triangulation techniques were applied to fill the gaps and to present a more meaningful picture of the market. To forecast global head
and neck cancer therapeutics market, TechSci Research used various forecast techniques such as:
✓ Moving Average
✓ Time Series Analysis
✓ Regression Analysis
✓ Econometric and Judgmental Analysis

22. 22
Research Methodology
TechSci Research used its own forecast tool, which is based on the growth of various allied industries in respective regions. TechSci Research
also used the impact analysis during short, medium and long term period to estimate the demand and to reach accurate market numbers. It
should be noted that the figures compiled are only for the organized market including market share data.
Partial List of Companies Interviewed Key Secondary Sources
▪ AstraZeneca Plc.
▪ Astellas Pharma Inc.
▪ AB Science SA
▪ Bristol-Myers Squibb Company
▪ Boston Biomedical, Inc.
▪ Eli Lilly and Company
▪ F. Hoffmann-La Roche Ltd. (Genentech, Inc.,)
▪ Fresenius Medical Care AG & Co. KGaA
▪ Sun Pharmaceutical Industries Ltd.
▪ Teva Pharmaceutical Industries Limited
▪ Merck & Co., Inc.
▪ Pfizer Inc.
▪ Sanofi S.A.
▪ Bayer AG
▪ AbbVie Inc.
▪ World Bank
▪ TechSci Research Proprietary Database & Knowledge
Repository
▪ Company Annual Reports
▪ Industry Magazines
▪ Industry Reports
▪ News Dailies

23. 23
Industry Brief
The growing prevalence of different types of head and neck cancers is expected to drive the growth of Global Head and Neck Cancer Therapeutics through
2027.
According to TechSci report on, “Global Head and Neck Cancer Therapeutics Market - By Region, Competition Forecast & Opportunities, 2027”. Global
Head and Neck Cancer Therapeutics Market stood at USD2024.33 million in 2021 and is expected to grow at an impressive rate of 7.22% during the
forecast period. This can be ascribed to the growth in research and development activities related to cancer treatment and developing new treatment
options. The rising incidence of various types of cancer has led to an increase in demand for developing therapies and drugs to treat them. This, in turn,
has made many government agencies, academic & research institutions, and biotechnology & pharmaceutical companies focus on a new therapy or
drug development. These organizations are increasing their research & development activities related to cancer diagnostics and therapeutics.
However, there are a lot of complications and post-surgery risks associated with various head and neck cancer surgeries. These risks or complications
include temporary or permanent loss of voice, hearing loss is also observed in certain cases, faulty speech, among others. Also, there are a lot of side
effects associated with chemotherapy, including harm caused to the healthy cells and cancerous cells, loss of appetite, nausea, pain, vomiting, hair
loss, tiredness, anemia, sleep problems, and others.
Global Head and Neck Cancer Therapeutics Market is segmented by type, by diagnostic methods, by treatment type, by disease indication, by route of
administration, by therapeutic class, by end user, by region and company. Based on type, the global head and neck cancer therapeutics market can be
split into diagnostic methods and treatment types. Diagnostic methods dominated the market with a share of around 56.89% since Diagnostic methods
form an integral part of the development of a treatment or therapy. Hence, accurate and precise diagnosis is required for developing the right treatment.
Diagnostic Methods such as Biopsy, Imaging, and Endoscopy not only help in the early diagnosis and detection of cancer but are done during the
treatment also in order to identify the cancer progression stages or whether the treatment provided is helping in the treatment and elimination of
different types of head and neck cancer. Based on disease indication, the market can be fragmented into Lip and Oral Cavity Cancer, Laryngeal
Cancer, Oropharyngeal Cancer, Nasopharyngeal Cancer, Salivary Gland Cancer and Hypopharyngeal Cancer. The Lip and Oral Cavity Cancer is
expected to dominate the market through 2027 on account of the growing prevalence of this cancer type. According to Globocan, 377,713 new cases of
lip and oral cavity cancer were reported in 2020 and along with this number of reported deaths caused due to lip and oral cancer were around 177,757.
A partial list of leading companies in the Global Head and Neck Cancer Therapeutics Market includes Eli Lilly and Company, Bristol Myers Squibb
Company, Sanofi S.A., Merck & Co., Inc., Pfizer Inc, AbbVie Inc., Bayer AG, F. Hoffmann-La Roche Ltd., Fresenius Medical Care AG & Co. KGaA, Sun
Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Limited, AstraZeneca Plc., Astellas Pharma Inc., AB Science SA, Boston Biomedical,
Inc.
The Asia Pacific region is expected to register the fastest growth during the forecast period. This can be attributed to the growing prevalence of different
types of head and neck cancers in the region, especially in two of the world’s highly populated countries, China and India.
Additionally, extensive research & development activities, ongoing clinical trials, increasing investments, expansion of companies along with their
manufacturing sites in the region especially in countries like China, Japan, Singapore, among others for the development of therapies and drugs for the
treatment of different types of head and neck cancers is further expected to support the market growth in the region.” said Mr. Karan Chechi, Research
Director with TechSci Research, a research based global management consulting firm.

24. 24
Sample Data - Snapshot
5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
2017 2021 2022E 2027F
CAGR By Value
XX%
CAGR By Value
YY%
Global Head and Neck Cancer Therapeutics Market Size, By Value (USD Million), 2017–2027F
North America Head and Neck Cancer Therapeutics Market Share, By Diagnostic Methods, By Value, 2017–2027F
25%
25%
25%
25%
25%
25%
25%
25%
25%
25%
25%
25%
25%
25%
25%
25%
25%
25%
25%
25%
25%
25%
25%
25%
25%
25%
25%
25%
25%
25%
25%
25%
25%
25%
25%
25%
25%
25%
25%
25%
25%
25%
25%
25%
2017
2018
2019
2020
2021
2022E
2023F
2024F
2025F
2026F
2027F
Biopsy Imaging Endoscopy Others
North America Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Value, 2017–2027F
20%
20%
20%
20%
20%
20%
20%
20%
20%
20%
20%
20%
20%
20%
20%
20%
20%
20%
20%
20%
20%
20%
20%
20%
20%
20%
20%
20%
20%
20%
20%
20%
20%
20%
20%
20%
20%
20%
20%
20%
20%
20%
20%
20%
20%
20%
20%
20%
20%
20%
20%
20%
20%
20%
20%
2017
2018
2019
2020
2021
2022E
2023F
2024F
2025F
2026F
2027F
Surgery Radiation Therapy Chemotherapy Immunotherapy Targeted Therapy

25. 25
Report Ordering
To View Sample OR Purchase Report
License Type Price
Single User License $4900
Multi-User License $5900
Custom Research License $8900
Report Name: GLOBAL HEAD AND NECK CANCER THERAPEUTICS MARKET
FORECAST & OPPORTUNITIES
2017 – 2027

26. About Us & Disclaimer
TechSci Research is a global market research and consulting company with offices in the US, UK and India. TechSci Research provides market research
reports in number of areas to organizations. The company uses innovative business models that focus on improving productivity, while ensuring creation of high-
quality reports. The proprietary forecasting models use various analyses of both industry-specific and macroeconomic variables on a state-by-state basis to
produce a unique ‘bottom-up’ model of a country, regional and global industry prospects. Combined with the detailed analysis of company activity and industry
trends, the result is a uniquely rich evaluation of the opportunities available in the market.
Related Reports
• Saudi Arabia CT Scanners Market By Slice (8-slice, 16-slice, 32-slice, 64-slice, 128-slice & above), By Modality (Fixed v/s Mobile), By Device
Architecture (O-arm v/s C-arm), By Application (Cardiology, Oncology, Neurology, Others), By End Users (Hospitals, Diagnostic Centers, Others), By
Region, Competition, Forecast & Opportunities, 2027
• Saudi Arabia X-Ray Systems Market By Modality (Direct Radiography v/s Computed Radiography) By Mobility (Stationary v/s Mobile) By Type (Digital
v/s Analog) By Application (Cardiovascular, Respiratory, Dental, Mammography, Others) By End User (Hospitals & Clinics, Diagnostic Centers,
Others) By Region, Competition Forecast & Opportunities, 2026
The contents of this report are based on information generally available to the public from sources believed to be reliable. No representation is made that it is timely,
accurate or complete. TechSci Research has taken due care and caution in compilation of data as this has been obtained from various sources including which it considers
reliable and first hand. However, TechSci Research does not guarantee the accuracy, adequacy or completeness of any information and it is not responsible for any errors or
omissions or for the results obtained from the use of such information and especially states that it has no financial liability whatsoever to the subscribers / users of this
report. The information herein, together with all estimates and forecasts, can change without notice. All the figures provided in this document are indicative of relative market
size and are strictly for client’s internal consumption. Usage of the same for purpose other than internal will require prior approval of TechSci Research.
TechSci Research – North America
708 Third Avenue, Manhattan,
New York, United States
Tel: +1- 646- 360- 1656
Email: sales@techsciresearch.com
www.techsciresearch.com
Disclaimer
TechSci Research – Europe
54, Old brook, Bretton,
Peterborough,
United Kingdom
Email: sales@techsciresearch.com
www.techsciresearch.com
TechSci Research – Asia-Pacific
B – 44, Sector – 57, Noida, National Capital
Region, U.P. - India
Tel: +91-120-4523900
Email: sales@techsciresearch.com
www.techsciresearch.com